Staben Steven, the Chief Scientific Officer of Lycia Therapeutics, Inc., has disclosed his stock ownership in the company through a recent SEC filing. This filing, dated October 22, 2026, is significant as it reveals Steven's financial stake and the stock options he holds, which may influence the company's leadership dynamics.

Lycia Therapeutics, Inc. operates in the biological products sector, focusing on innovative therapies. The company is incorporated in Delaware and is publicly traded under the ticker symbol LYCA. This filing is part of a series of recent disclosures by Steven, including a subsequent Form 4 filing scheduled for October 26, 2026.

According to the filing (accession number 0002159565-26-000003), Staben Steven currently owns 55,448 shares of common stock. Additionally, he holds several stock options that allow him to purchase more shares at specified prices. The options include:

  • 166,345 shares at an exercise price of $1.63, expiring on October 19, 2031.
  • 155,255 shares at an exercise price of $2.44, expiring on June 27, 2034.
  • 22,179 shares at an exercise price of $2.35, expiring on February 9, 2036.
  • 110,896 shares at an exercise price of $3.70, expiring on August 10, 2036.

These holdings indicate a substantial commitment to the company's future, which may affect investor confidence and the company's strategic direction. The filing also notes that Steven is a ten percent owner, highlighting his significant influence within the organization.

The impact of this disclosure may extend beyond the company itself. As the biological products sector continues to evolve, transparency in executive ownership can lead to increased scrutiny from investors and regulatory bodies. Stakeholders in the industry may closely monitor such filings to gauge executive confidence and company performance.

Looking ahead, the next filing from Staben Steven is expected on October 26, 2026, which may provide further insights into his ownership changes or additional transactions. As the industry navigates complex dynamics, disclosures like this will remain crucial for understanding executive alignments and company trajectories.